查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1375968

肝癌治疗药物市场规模、份额和趋势分析报告：2023-2030 年按药物类别、地区和细分市场分類的趋势

Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug Class (Targeted Therapy, Immunotherapy, Chemotherapy), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 92 Pages | 商品交期: 2-10个工作天内

价格

肝癌治疗药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球肝癌药物市场规模预计将达到78.3亿美元，预测期内年复合成长率为15.3%。

肝癌市场的成长很大程度上取决于新药的可得性、强大的产品线的存在以及公众意识的提高等因素。肝癌患者数量的增加是由于不健康的生活习惯和老年人口的增加所造成的。这有利于肝癌药物市场。针对不能耐受多吉美患者的二线治疗的开发预计将对肝癌领域产生重大影响。

肝癌是全球第五大常见癌症，占癌症死亡人数的 9.0%。 2012年，新诊断肝癌782,451人，肝癌死亡745,533人。由于其极具侵袭性和低存活率，原发性肝癌仍是一个重要的公共卫生问题。肝细胞癌占原发性肝癌的大部分（75-90%）。肝癌的许多显着原因，包括肝炎感染和肝硬化，都是可以改变的，改变生活方式和接种肝炎疫苗等预防策略为降低肝癌的发病率和死亡率提供了良好的前景。

肝癌治疗药物市场报告亮点

  • 2022年，北美将占市占率超过43.20%。多种产品的推出、新疗法的采用增加以及庞大的目标人口正在促进该地区的市场成长。
  • 近期多个新药的核准是扩大肝癌治疗市场的关键因素之一。免疫肿瘤学领域的新产品和联合治疗预计将在未来年度改变游戏规则。
  • 特别是，包括检查点抑制剂在内的联合治疗将被引入一线治疗中，以满足关键的未满足需求，例如克服肿瘤抗药性、提高无恶化生存期和维持生活品质。
  • 肝癌市场管道具有高度创新性和多样性。大量未满足的需求为开发创新的一流治疗方法提供了绝佳的机会。近年来，溶瘤病毒和RNA干扰（RNAi）技术等创新治疗方法在市场上获得了巨大的关注。

目录

第1章调查方法与范围

第2章执行摘要

第3章

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 普及和成长前景图
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 肝癌治疗药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章治疗药物市场：药物类别的估计与趋势分析

  • 肝癌药物市场：要点
  • 肝癌药物市场：2022 年和 2030 年药物类别趋势和市场占有率分析
  • 标靶治疗
  • 免疫疗法
  • 化疗

第5章治疗药物市场：区域估计与趋势分析

  • 区域展望
  • 按地区分類的肝癌药物市场：要点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第6章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • Exelixis, Inc.
    • Merck KGaA
Product Code: GVR-2-68038-513-7

Liver Cancer Drug Market Growth & Trends:

The global liver cancer drug market size is expected to reach USD 7.83 billion by 2030, registering a CAGR of 15.3% during the forecast period, according to a new report by Grand View Research, Inc.. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights:

  • The North America accounted for more than 43.20% of the market in 2022. Multiple product launches, increasing adoption of novel therapeutics, and presence of a large target population are contributing to the growth of the market in the region
  • Approval of multiple novel drugs in recent years is one of the key factors augmenting the liver cancer treatment market. New immuno-oncology products and combination therapies are anticipated to change the landscape over the next years.
  • Combination regimens, specifically those including checkpoint inhibitors, will be introduced in the first-line setting to target major unmet needs, including overcoming tumour resistance, improving progression free survival, and maintaining quality of life
  • The liver cancer market pipeline is highly innovative and diverse. The market offers tremendous opportunities to develop breakthrough first-in-class therapies due to high unmet needs. In recent years, innovative treatment approaches such as oncolytic viruses or RNA interference (RNAi) technology have gained significant traction in the market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Class
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Liver Cancer Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Liver Cancer Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Liver Cancer Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Liver Cancer Drugs Market: Key Takeaways
  • 4.2. Liver Cancer Drugs Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Targeted Therapy
    • 4.3.1. Targeted therapy market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.4. Immunotherapy
    • 4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.5. Chemotherapy
    • 4.5.1. Chemotherapy market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 5. Liver Cancer Drugs Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Liver Cancer Drugs Market by Region: Key Takeaways
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Denmark
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Norway
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. South Africa
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. Bayer AG
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Bristol-Myers Squibb Company
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Eisai Co., Ltd.
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Exelixis, Inc.
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Merck KGaA
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 North America liver cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Canada liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 Europe liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 Europe liver cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 8 Germany liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 UK liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 France liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 Italy liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 Spain liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Denmark liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Sweden liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 Norway liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific liver cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 18 China liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 Japan liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 India liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Australia liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Thailand liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 South Korea liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 24 Latin America liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Latin America liver cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 26 Brazil liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Mexico liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 Argentina liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa liver cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 South Africa liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 UAE liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Kuwait liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Liver cancer drugs: Market outlook
  • Fig. 8 Liver cancer drugs: Competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Liver cancer drugs market driver impact
  • Fig. 13 Liver cancer drugs market restraint impact
  • Fig. 14 Liver cancer drugs market strategic initiatives analysis
  • Fig. 15 Liver cancer drugs market: Drug class movement analysis
  • Fig. 16 Liver cancer drugs market: Drug class outlook and key takeaways
  • Fig. 17 Targeted therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Immunotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Global liver cancer drugs market: Regional movement analysis
  • Fig. 21 Global liver cancer drugs market: Regional outlook and key takeaways
  • Fig. 22 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)